Skip to main content

Advertisement

Table 2 The ranks for GBM drugs in the three evaluation sets generated by our approach and Hoehndorf’s approach

From: Towards precision medicine-based therapies for glioblastoma: interrogating human disease genomics and mouse phenotypes

Evaluation drug (set) Our approach Hoehndorf’s approach p-value
Approved drugs Temozolomide 6.7 % NA NA
  Carmustine 10.7 % NA NA
  Bevacizumab 24.4 % 67.9 % NA
Potential drugs (clinical trials) 7.8 % 45.4 % p=0.003
Off-label drugs (post-marketing surveillance) 15.3 % 44.2 % p=0.02
Combination 9.2 % 45.6 % p=0.0003